ALT normal range: how to interpret this liver blood test

What ALT measures

Alanine aminotransferase, usually shortened to ALT, is an enzyme found mainly in liver cells called hepatocytes. It helps process amino acids. When cells are injured, more of the enzyme can enter the bloodstream, making ALT useful as a marker of possible liver cell injury.

There is no single normal range that applies to every laboratory and person. A range of 7–56 U/L is often quoted, but laboratories use different methods and reference populations. Research on U.S. population data has also questioned how best to set the upper limit. Start with the interval printed on your own report, then consider your history and other findings. Source

A healthy person normally has some ALT in the blood. The body produces the enzyme as part of ordinary metabolism, and small amounts reach the circulation during normal cell turnover. A higher result can prompt investigation, but it is not a direct measurement of how much liver tissue has been damaged or how well the liver is functioning.

ALT is also not entirely specific to the liver. Muscle injury and strenuous exercise can affect it. Conversely, a normal ALT does not rule out fatty liver disease or advanced liver disease. The result is a clue to interpret, not a diagnosis on its own.

Reference ranges and proposed healthy limits

A laboratory reference interval describes a population and a measurement method; it is not a universal target for optimal health. Some laboratories use upper limits near 40 or 56 U/L. The American College of Gastroenterology’s 2017 guideline discusses lower healthy upper limits, approximately 29–33 U/L for men and 19–25 U/L for women, and recommends assessing values above them. These figures should be interpreted clinically rather than used as a stand-alone diagnosis. Source

Age and sex also affect the intervals a laboratory reports. The following table gives the Quest Diagnostics intervals cited in the source material. It is an example, not a substitute for the range on your current report. Laboratory directory

Age	Male (U/L)	Female (U/L)
Under 28 days	3–25	3–25
28 days to 11 months	4–35	3–30
1–3 years	5–30	5–30
4–12 years	8–30	8–24
13–15 years	7–32	6–19
16–19 years	8–46	5–32
20 years and older	9–46	6–29

The debate about lower limits reflects a real concern: a reference population can include people with unrecognized liver disease. A 2002 study proposed upper limits of 30 U/L for men and 19 U/L for women after selecting a healthier reference group. A separate 2004 cohort study linked aminotransferase levels within the then-normal range to subsequent liver-related mortality. Neither study establishes these numbers as thresholds for diagnosing metabolic syndrome. Source Source

Your age, metabolic health, medicines, alcohol exposure, symptoms, and previous results help determine what comes next. A 25-year-old athlete and a 55-year-old with prediabetes may need different assessments, but that does not establish a personalized “optimal ALT” number for either person.

For example, an ALT of 45 U/L accompanied by normal AST, triglycerides, and glucose presents a different pattern from an ALT of 45 with several other abnormalities. Neither pattern is enough to establish or exclude a cause. Trends can be useful, but a rising trend, a persistent elevation, and a single markedly abnormal result need different responses.

What a high ALT can mean

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is a common cause of persistently elevated ALT. It overlaps substantially with the condition formerly called nonalcoholic fatty liver disease, NAFLD, although the newer terminology also changes the diagnostic criteria. A 2023 review of studies conducted from 1990–2019 estimated global NAFLD prevalence at about 30%; that is not a current prevalence ceiling restricted to developed countries. Source Source

Other possibilities include medicines or supplements, viral hepatitis, alcohol-related injury, and muscle injury. The pattern of other blood tests, the timing of the change, and a review of exposures help narrow the possibilities. Fatty liver is common, but an ALT result alone cannot identify it as the cause. Source

A result above 1,000 U/L can accompany serious acute injury and needs urgent medical assessment. At any ALT level, symptoms such as jaundice, confusion, or severe illness can change the urgency. The number should not be used to decide that a symptomatic person is safe to wait simply because it is below a particular threshold.

What a low ALT can mean

An isolated low ALT is often not concerning, especially when the rest of the assessment is reassuring. It does not, however, certify excellent liver health. In older adults, persistently very low ALT has been associated with frailty, low muscle mass, disability, and poorer survival. These are population associations, not a diagnosis made from a single result. Source

ALT activity also depends on vitamin B6. Low B6 status can affect enzyme activity, but an ALT below 10 U/L is not a validated stand-alone test for B6 deficiency. Nutrition, the laboratory method, muscle mass, and the broader clinical picture all matter. Do not use a low ALT result alone as a reason to start high-dose supplementation. Source

The interpretation is therefore different from simply assuming that lower is always better. A stable low value in a healthy person and a newly very low value in an older person losing strength may call for different conversations.

How the ALT test is done

The test uses a blood sample, usually taken from a vein in the arm. ALT alone often does not require fasting, but preparation depends on the full set of tests ordered and the laboratory’s instructions. Other tests taken at the same appointment may require a fasting period. Test information

An automated chemistry analyzer measures enzyme activity. Results are usually reported in units per liter, U/L, or international units per liter, IU/L. Many laboratories return routine results within 24–48 hours, but turnaround varies; that interval is not guaranteed.

Time of day generally has a smaller effect than many clinical factors. A U.S. population study did not find a clinically important overall daily variation, although it reported a small evening difference among women. For follow-up, consistent collection conditions can still make comparisons easier. Source

Recent exercise is worth mentioning. In a small study of healthy men, a weightlifting session increased ALT and several muscle-related markers for at least seven days. The effect is not necessarily limited to exercise in the previous 24 hours. This does not mean every workout causes an abnormal result, but it can help explain an unexpected result in context. Source

There is no single testing schedule for everyone. A three- to six-month interval may be appropriate in some stable situations; a new, marked, or symptomatic elevation may need assessment much sooner. A normal ALT does not automatically require annual repeat testing in an otherwise healthy person. Medicines, known disease, symptoms, and the reason for the first test guide follow-up. Source

What can influence ALT?

Diet can influence liver fat and metabolic health, but it is useful to distinguish an association from a demonstrated treatment effect. An observational study linked higher fructose consumption to NAFLD. A controlled-feeding meta-analysis found that replacing other carbohydrates with fructose calorie for calorie did not show the same adverse liver-marker effects as adding high doses of fructose on top of an existing diet. Extra calories matter to the interpretation. These papers do not establish that removing added sugar will lower everyone’s ALT within a fixed number of weeks. Source Source

For people with excess weight and fatty liver disease, sustained weight loss can improve liver fat and blood markers. A loss of roughly 5–10% of body weight can be clinically meaningful, but it does not guarantee normal ALT or reversal of every stage of liver disease. A weight-loss meta-analysis supports improvements across several NAFLD markers while also showing why the condition and outcome being measured matter. Source

Alcohol can contribute to liver injury, particularly with heavy or repeated binge drinking. A normal ALT does not establish that a person’s alcohol consumption is safe. Some alcohol-related elevations improve within weeks after stopping, but two to four weeks is not a universal recovery timetable. People at risk of alcohol withdrawal need medical support when reducing or stopping intake.

Exercise can improve insulin sensitivity, body composition, and liver fat. Research on exercise-based interventions in NAFLD supports benefits, although not every program or liver marker responds equally. Both aerobic and resistance activity can be useful components of care. This longer-term benefit is compatible with a temporary ALT rise after an unusually strenuous workout. Source

These measures address some common contributors to elevated ALT. They do not replace investigating other causes, including viral hepatitis or medication-related injury. Prescribed medicines should be reviewed with the treating clinician rather than stopped solely because of an isolated test result.

Reading ALT alongside other laboratory results

ALT rarely identifies the cause of an abnormal result on its own. AST, or aspartate aminotransferase, is found in the liver and in other tissues, including muscle. The relationship between AST and ALT can provide clues, but neither the AST-to-ALT ratio nor its inverse is a diagnostic shortcut. ALT is often higher in some liver conditions; AST can predominate in others or after muscle injury. Source

Alkaline phosphatase, ALP, and gamma-glutamyl transferase, GGT, help describe a different pattern. A raised ALP may come from the liver and bile ducts or from non-liver sources such as bone. GGT can help establish whether an ALP rise is liver-related, but an elevated GGT is nonspecific and does not by itself diagnose alcohol-related injury or fatty liver. Source

Metabolic markers add context. High triglycerides or glucose alongside elevated ALT can strengthen suspicion of metabolic dysfunction and fatty liver. Normal glucose and triglycerides do not exclude MASLD, just as abnormal values do not prove it is the only explanation for the ALT result.

Bilirubin provides additional information, but a normal bilirubin does not guarantee that liver function is preserved. Raised bilirubin also has causes other than severe liver injury, including increased red blood cell breakdown or benign inherited conditions. Clinicians may consider the bilirubin pattern, albumin, clotting measures, symptoms, and imaging when assessing function and urgency. A new combination of jaundice and abnormal liver tests deserves prompt assessment.

What ALT can contribute to early detection

Fatty liver disease is common and may cause no symptoms for years. An unexplained or persistent ALT elevation can be one reason to investigate, creating an opportunity to address metabolic risk and liver disease before complications develop.

ALT alone is not a reliable screening test for advanced fibrosis. People with significant disease can have results within the laboratory range. The AASLD guidance emphasizes assessment based on metabolic risk, clinical findings, and appropriate fibrosis tests rather than relying only on repeated ALT measurements. A falling or normal ALT can be useful information without proving that all underlying disease has resolved. Source

Frequently asked questions

What counts as a high ALT?

A result above your laboratory’s upper limit is flagged as high, but the limit varies. The often-quoted upper value of 56 U/L is not universal, and clinical guidance discusses lower healthy limits. Values in the 50–150 U/L range can occur with fatty liver, medicines, alcohol, viral illness, and other causes; the value does not diagnose one of them.

A result above 1,000 U/L warrants urgent assessment for acute injury. Urgency at lower values depends on symptoms, the change from baseline, other tests, and possible exposures, not just the ALT number.

How do ALT reference ranges differ by age?

In the Quest example above, adults aged 20 or older have intervals of 9–46 U/L for males and 6–29 U/L for females. At ages 16–19, the listed intervals are 8–46 and 5–32 U/L, respectively. For children aged 4–12, they are 8–30 and 8–24 U/L.

These are laboratory-specific examples. Compare a result with the interval on the child’s or adult’s actual report, and ask the clinician how age, symptoms, and other findings affect interpretation. Laboratory directory

Is an ALT of 63 high?

An ALT of 63 U/L is above many adult reference intervals, including the commonly quoted 7–56 U/L range. It is usually a modest elevation relative to those limits, but it does not directly measure the severity of tissue damage.

Possible explanations include fatty liver, medicines, alcohol exposure, viral illness, and muscle-related effects. A clinician can review the context and decide whether and when to repeat the test or investigate further, especially if the elevation persists.

Is an ALT of 200 concerning?

An ALT of 200 U/L is clearly elevated against most adult reference intervals and warrants timely medical evaluation. It does not by itself prove severe liver damage or determine whether emergency care is needed.

The assessment may consider hepatitis, medication-related injury, fatty liver, and other causes. Jaundice, confusion, severe symptoms, a rapid rise, or concerning additional tests make the situation more urgent. Do not wait for a routine retest if the treating team advises immediate evaluation.

What ALT range is optimal for liver health?

There is no universally validated personal optimal target. Prati and colleagues proposed healthy upper limits of 30 U/L for men and 19 U/L for women; the ACG guideline discusses approximately 29–33 and 19–25 U/L. These numbers help clinicians think about results that a laboratory might otherwise label normal.

They do not diagnose metabolic syndrome or establish that progressively lower ALT is always healthier. Trends, risk factors, other findings, and the limits of ALT as a disease marker remain important.

How quickly can ALT change?

ALT can rise over days during an acute injury and may fall as the cause resolves. Some alcohol-related or medication-related elevations change over weeks, but a two- to four-week improvement is not guaranteed. Medication changes should be agreed with the prescriber.

Diet and sustained weight loss, often discussed in the range of 5–10% for people with excess weight and fatty liver, may improve results over weeks to months. The pace depends on the cause and severity of the condition. A lower ALT does not always mean every aspect of liver disease has resolved.

Which lifestyle changes can lower a high ALT?

When metabolic dysfunction and excess liver fat are involved, sustainable weight management, fewer sugar-sweetened drinks, an overall nutritious eating pattern such as a Mediterranean-style diet, and regular activity can help. Aerobic and resistance exercise both have a role. A sustained 5–10% weight reduction can be meaningful for some people with excess weight, but it is not a universal prescription or a guaranteed normalization threshold.

Alcohol intake also deserves review, and some people need support to stop safely. If another cause is responsible for the ALT elevation, lifestyle changes alone may not address it. The aim is to treat the cause and improve health, not simply lower a laboratory number.

Should I fast before an ALT blood test?

ALT alone often does not require fasting. When it is ordered with glucose, lipids, or other chemistry tests, the specific panel and clinical question may require a fasting period, sometimes 8–12 hours. Not all lipid tests require fasting.

Follow the instructions from the practice or laboratory, and tell them about medicines, supplements, and recent strenuous exercise. Do not stop prescribed treatment just to prepare for a test unless instructed to do so.

Sources and references

Ruhl CE, Everhart JE (2012). Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology (Baltimore, Md.), 55(2), 447-54. https://doi.org/10.1002/hep.24725 Publication

Kwo PY, Cohen SM, Lim JK (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American journal of gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517 Publication

Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I (2004). Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (Clinical research ed.), 328(7446), 983. https://doi.org/10.1136/bmj.38050.593634.63 Publication

Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of internal medicine, 137(1), 1-10. https://doi.org/10.7326/0003-4819-137-1-200207020-00006 Publication

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, … NAFLD Nomenclature consensus group (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (Baltimore, Md.), 78(6), 1966-1986. https://doi.org/10.1097/HEP.0000000000000520 Publication

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md.), 77(4), 1335-1347. https://doi.org/10.1097/HEP.0000000000000004 Publication

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R (2023). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), 77(5), 1797-1835. https://doi.org/10.1097/HEP.0000000000000323 Publication

Pratt DS, Kaplan MM (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. The New England journal of medicine, 342(17), 1266-71. https://doi.org/10.1056/NEJM200004273421707 Publication

Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP (2019). Drug-induced liver injury. Nature reviews. Disease primers, 5(1), 58. https://doi.org/10.1038/s41572-019-0105-0 Publication

Leise MD, Poterucha JJ, Talwalkar JA (2014). Drug-induced liver injury. Mayo Clinic proceedings, 89(1), 95-106. https://doi.org/10.1016/j.mayocp.2013.09.016 Publication

Mazzanti G, Di Sotto A, Vitalone A (2015). Hepatotoxicity of green tea: an update. Archives of toxicology, 89(8), 1175-91. https://doi.org/10.1007/s00204-015-1521-x Publication

Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, Bandinelli S, Antonelli Incalzi R, Picardi A (2018). Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival. The journals of gerontology. Series A, Biological sciences and medical sciences, 73(7), 925-930. https://doi.org/10.1093/gerona/glx126 Publication

Ueland PM, Ulvik A, Rios-Avila L, Midttun, Ø., Gregory JF (2015). Direct and Functional Biomarkers of Vitamin B6 Status. Annual review of nutrition, 35, 33-70. https://doi.org/10.1146/annurev-nutr-071714-034330 Publication

Ruhl CE, Everhart JE (2013). Diurnal variation in serum alanine aminotransferase activity in the US population. Journal of clinical gastroenterology, 47(2), 165-73. https://doi.org/10.1097/MCG.0b013e31826df40a Publication

Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkström V, Ekelund M (2008). Muscular exercise can cause highly pathological liver function tests in healthy men. British journal of clinical pharmacology, 65(2), 253-9. https://doi.org/10.1111/j.1365-2125.2007.03001.x Publication

Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF (2008). Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of hepatology, 48(6), 993-9. https://doi.org/10.1016/j.jhep.2008.02.011 Publication

Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, Ha V, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Don-Wauchope AC, Beyene J, Kendall CW, Jenkins DJ (2014). Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European journal of clinical nutrition, 68(4), 416-23. https://doi.org/10.1038/ejcn.2014.8 Publication

Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, Jebb SA, Aveyard P (2019). Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA internal medicine, 179(9), 1262-1271. https://doi.org/10.1001/jamainternmed.2019.2248 Publication

Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C (2016). Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 14(10), 1398-411. https://doi.org/10.1016/j.cgh.2016.04.036 Publication

MedlinePlus, U.S. National Library of Medicine. ALT Blood Test. https://medlineplus.gov/lab-tests/alt-blood-test/